Enzovera Recombinant Human Type XVII Collagen (EV-COL-005) is a recombinant human collagen of ≥10 kDa, >90% purity, supplied in sponge form in 50 g and 100 g bags. Type XVII collagen (COL17A1 gene product) is a transmembrane collagen that serves as a structural anchor in the hemidesmosome — the adhesion complex linking basal keratinocytes to the basement membrane — and has emerged as a key regulator of hair follicle stem cell niche integrity, epidermal aging, and alopecia, positioning it as a compelling active ingredient and research tool for next-generation anti-hair-loss therapeutics and skin barrier biology.

Biology of Type XVII collagen. Unlike fibrillar collagens, Type XVII collagen is a non-fibrillar transmembrane collagen — also known as BP180 or BPAG2 — with a single transmembrane domain, an intracellular N-terminal domain, and a long extracellular C-terminal ectodomain containing collagenous triple-helix repeat sequences. In epidermal basal keratinocytes, Type XVII collagen is an integral structural component of hemidesmosomes, linking the intracellular intermediate filament cytoskeleton (through plectin and BP230/dystonin) to the laminin-332-containing extracellular basement membrane. This anchoring function is essential for epidermal integrity: autoantibodies targeting the BP180 ectodomain cause bullous pemphigoid and gestational pemphigoid, characterized by hemidesmosome disruption and blister formation at the dermal-epidermal junction — confirming the non-redundant structural role of Type XVII collagen in basal epithelium.

Role in hair follicle aging and alopecia. Recent research has identified Type XVII collagen as a central regulator of hair follicle stem cell (HFSC) maintenance during aging. Progressive decline of COL17A1 expression in HFSCs results in loss of quiescence, premature differentiation, and depletion of the follicular stem cell pool — directly driving progressive hair thinning and follicle miniaturization. Restoration of COL17A1 levels preserves HFSC identity and delays aging-associated hair cycle deterioration. These findings position recombinant Type XVII collagen and COL17A1-activating compounds as research tools and potential actives for anti-hair-loss cosmeceuticals and pharmaceuticals operating beyond the established DHT-androgen receptor axis targeted by finasteride and minoxidil.

Recommended applications:

• Hair loss and alopecia research: HFSC aging biology, COL17A1 depletion models, and niche maintenance studies
• Anti-hair-loss cosmeceutical active ingredient and formulation development
• Basement membrane biology: hemidesmosome assembly and basal keratinocyte adhesion research
• Bullous pemphigoid diagnostic antigen preparation and autoantibody detection assay development
• Epidermal aging model systems and skin barrier function research
• Hair follicle organoid culture: stem cell niche extracellular matrix component
• Topical scalp formulations targeting follicular microenvironment collagen restoration